Cancer Treatment Study with Ivermectin and Mebendazole

Most of them are getting scans every three months.

These are patients who had... The most common cancer was

prostate in man, b- breast in a woman, and then lung cancer, and then

after that, much smaller fractions. So mainly the solid organ cancers.

They had background chemotherapy, radiation, surgery.

So they go on ivermectin, mebendazole, just under 200

patients, and they fill out all the information.

I'll go with safety first. The rate of side effects with

mebendazole and ivermectin is about 25%.

So just to be fair, it can be some GI intolerances, some other

symptoms. So that's the s-

But nothing serious. I mean, uh, uh, you know-

Nothing

... no one likes GI intolerance, but-

Nothing serious. But it goes to show you it's a realistic

study when you-

Right.

Anytime you're saying there's no side effects-

Right

... you have to understand this, this is a real study.

There was 84% n- net clinical benefit.

Now, that breaks down to 36%

said that their disease stayed the same,

48% said that their cancer actually improved,

that there was reduction in the tumor volume or some other

marker of, of resolution or improvement, and then

15% of patients actually worsened.

So the overall, for cancer, that's

a really good number. There are s- a lot of cancer protocols where

patients just get a smidgen of improvement.

Here with ivermectin, mebendazole, either one tablet a day

and then under doctor's instructions...

So for instance, in my practice, I have patients take one twice a day.

Boy, there's a big benefit